ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017
/PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet...
Mccormick Place United States Oricar Technology Platform Prnewswire Oricell Therapeutics Co Ltd Refractory Multiple Myeloma Oral Abstract
Source: prnewswire.com